Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prefrontal Cortex Activation and Stopping Performance Underlie the Beneficial Effects of Atomoxetine on Response Inhibition in Healthy Volunteers and Those With Cocaine Use Disorder.
Zhukovsky P, Morein-Zamir S, Ziauddeen H, Fernandez-Egea E, Meng C, Regenthal R, Sahakian BJ, Bullmore ET, Robbins TW, Dalley JW, Ersche KD. Zhukovsky P, et al. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Nov;7(11):1116-1126. doi: 10.1016/j.bpsc.2021.08.010. Epub 2021 Sep 8. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022. PMID: 34508901 Clinical Trial.
Anthropometry in antipsychotic-naïve first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples.
Garcia-Rizo C, Crespo-Facorro B, Oliveira C, Gómez-Revuelta M, Kirkpatrick B, Son JM, de la Hoz LC, Garriga M, Garrido-Torres N, Bernardo M, Fernandez-Egea E, Vázquez-Bourgon J. Garcia-Rizo C, et al. Among authors: fernandez egea e. Schizophr Res. 2024 Apr;266:216-226. doi: 10.1016/j.schres.2024.02.020. Epub 2024 Feb 29. Schizophr Res. 2024. PMID: 38428119
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study.
Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Castro-Fornieles J, Bergé D, Escartí MJ, Ibañez Á, Penadés R, Sánchez-Torres AM, Bernardo M; PEPs Group. Mezquida G, et al. Schizophr Res. 2017 Nov;189:84-90. doi: 10.1016/j.schres.2017.01.047. Epub 2017 Feb 6. Schizophr Res. 2017. PMID: 28185786
The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.
Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Passetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JF, Nutt DJ, Lingford-Hughes AR; ICCAM Platform. Paterson LM, et al. J Psychopharmacol. 2015 Sep;29(9):943-60. doi: 10.1177/0269881115596155. Epub 2015 Aug 5. J Psychopharmacol. 2015. PMID: 26246443 Free article. Clinical Trial.
145 results